^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-0482

    i
    Other names: MK-0482
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    ILT-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    28d
    KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (clinicaltrials.gov)
    P1/2, N=450, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402) • ifinatamab deruxtecan (DS-7300) • vibostolimab (MK-7684) • MK-0482 • MK-4830
    2ms
    KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (clinicaltrials.gov)
    P1/2, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Phase classification: P2 --> P1/2
    Phase classification • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402) • ifinatamab deruxtecan (DS-7300) • vibostolimab (MK-7684) • MK-0482 • MK-4830
    6ms
    PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS (clinicaltrials.gov)
    P1, N=13, Completed, Presage Biosciences
    New P1 trial
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD163 (CD163 Molecule) • GZMB (Granzyme B)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    8ms
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    9ms
    KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (clinicaltrials.gov)
    P2, N=360, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2032 --> Feb 2039 | Trial primary completion date: Feb 2032 --> Feb 2039
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab (MK-7684) • MK-0482 • MK-4830
    11ms
    A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
    P1, N=12, Terminated, Merck Sharp & Dohme LLC | N=35 --> 12 | Active, not recruiting --> Terminated; Business Reasons
    Enrollment change • Trial termination
    |
    MK-0482
    11ms
    KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2032 --> Sep 2025 | Trial primary completion date: Feb 2032 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    12ms
    A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Merck Sharp & Dohme LLC | Phase classification: P1b --> P1 | Trial completion date: Aug 2025 --> Dec 2023 | Trial primary completion date: Aug 2025 --> Dec 2023
    Phase classification • Trial completion date • Trial primary completion date
    |
    MK-0482
    1year
    KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (clinicaltrials.gov)
    P2, N=360, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • vibostolimab (MK-7684) • MK-0482 • MK-4830
    1year
    KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    over1year
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1b, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    over1year
    A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
    P1b, N=35, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    MK-0482
    almost2years
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=15, Recruiting, Presage Biosciences | N=24 --> 15
    Enrollment change
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    over2years
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1b, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    over2years
    KEYNOTE-01B: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
    P2, N=120, Recruiting, Merck Sharp & Dohme Corp. | N=60 --> 120
    Enrollment change • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    over2years
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=24, Recruiting, Presage Biosciences | N=36 --> 24
    Enrollment change
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • 5-fluorouracil • MK-0482 • MK-4830 • dazostinag (TAK-676)
    over2years
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    over3years
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=36, Recruiting, Presage Biosciences | Not yet recruiting --> Recruiting | N=12 --> 36 | Initiation date: Feb 2021 --> Jun 2021
    Clinical • Enrollment open • Enrollment change • Trial initiation date
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)
    over3years
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Aug 2022 --> Jun 2024 | Trial primary completion date: Aug 2022 --> Jun 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    over3years
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | N=85 --> 230
    Clinical • Enrollment change • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    almost4years
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Presage Biosciences | Trial completion date: Dec 2030 --> Dec 2031 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Dec 2030 --> Dec 2031
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)
    4years
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Presage Biosciences
    Clinical • New P1 trial • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)